Posted by Michael Wonder on 13 Jun 2023
SMC accepts Rinvoq (upadacitinib) as a treatment option for adults with moderately to severely active Crohn’s disease in Scotland
12 June 2023 - The SMC decision is supported by data from three Phase 3 clinical trials demonstrating upadacitinib achieved the co-primary endpoints of clinical remission and endoscopic response at week 12 and week 52 (p<0.001 vs placebo).
AbbVie today announced that the Scottish Medicines Consortium has accepted Rinvoq (upadacitinib) for use within NHS Scotland as an option for moderately to severely active Crohn’s disease in adults who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, or for whom such therapies are not advisable.
